Abstract
Objective
More than 70% of hepatic alveolar echinococcosis (HAE) are inoperable. Thus, long-term, or even life-long, pharmacological treatment with benzimidazoles is necessary. For effective treatment, it is of great importance to employ imaging techniques to detect and monitor the non-resectable parasitic viability. Therefore, this study aimed to evaluate diffusion-weighted imaging (DWI) in assessing the viability of HAE in comparison to 18-fluoro-deoxyglucose (18F-FDG) positron emission tomography, combined with computed tomography (PET/CT).
Materials and Methods
Positron emission tomography, computed tomography and DWI (b-values: 0, 800 s/mm2) were retrospectively analysed in eight patients with clinically-verified HAE to, generate the apparent diffusion coefficient (ADC) map. The activity of HAE lesions in both techniques were determined independently by two radiologists according to the following standard: (+), marked focally or perilesionally increased FDG uptake/high signal intensity; (−), a hepatic defect without FDG uptake/no high signal intensity. Every lesion's maximum standardized uptake value (SUVmax) on the PET/CT images and mean ADC values on the parametric ADC maps were measured respectively. Results of PET/CT and DWI were compared on a per-lesion-basis. Pearson's correlation coefficient was assessed for statistical analysis.
Results
A total of 14 HAE lesions were detected. Eight lesions (diameter 3–15 cm) showed perilesional hyper-signal intensity on DWI. This was visualised on PET/CT as increased FDG uptake. They mainly existed in the lesion's border with normal liver parenchyma. Five lesions (diameter < 2 cm) were detected as nodular hyperintensity on DWI and a ‘hot spot’ on PET/CT in the same distribution. One patient, who had received oral drug therapy for three years showed significantly decreased perilesional hyperintensity on the DWI and a hepatic defect without any FDG uptake on PET/CT. Pearson's correlation coefficient indicated a significant inverse correlation of the ADC and the SUVmax (r = −0.67, p < 0.001).
Hepatic alveolar echinococcosis (HAE) is caused by the parasitic cestode Echinococcus multilocularis (E. multilocularis), which is endemic in many parts of the world. Without timely diagnosis and therapy, the prognosis is dismal–the eventual outcome in most cases is death. Surgical resection of primary lesions allows curative treatment. However, more than 70% of cases are inoperable at the time of diagnosis. In these cases, there is a tumor-like growth of the parasite with diffuse infiltration of “non-resectable” structures, or insufficient safety margins. In such cases, long-term or even life-long pharmacological treatment with benzimidazoles would be necessary (12).
It is of great importance, therefore, to employ imaging techniques that can detect and monitor the viability of inoperable HAE, which would help optimize therapeutic management. For instance, detection of dead parasites permits the duration of chemotherapy to be shortened. Likewise, for those with persistent or increasing disease activity, long-term medical treatment or other intervention is necessary. However, HAE viability cannot be obtained by conventional imaging techniques (i.e., ultrasound [US], computed tomography [CT], and MRI).
Previous studies have demonstrated the value of 18-fluoro-deoxyglucose positron emission tomography computed tomography (18F-FDG PET/CT) in assessing the viability of HAE. This imaging procedure is currently considered the best surrogate marker of parasite viability (34). Despite its value, PET/CT has several notable disadvantages. These include the need to use high radiation doses, tedious preparation procedures for 18F-FDG and the patient, and the lengthy time required for FDG uptake and scanning. In addition, PET/CT scanners are not as widely available as CT or MRI scanners.
To the best of our knowledge, diffusion-weighted imaging (DWI) sequence provides anatomical and functional details is rarely used in the assessment of HAE viability (56). However, we wondered it could be used without the notable disadvantages found with PET/CT. The aim of this study thus explores the value of DWI in assessing the viability of HAE by comparing its performance to that of PET/CT.
Eight patients with HAE were evaluated retrospectively at the first hospital of Xinjiang Medical University, including three females and five males. Institutional Review Board approval and the requirements for informed consent were obtained for all patients involved in this study. The age range of the patients was 15–58 years (mean age, 40.5 years). The diagnosis of HAE had been established by patients' pastoral life history, serology (specific antibodies against E. multilocularis with the Em2plus- enzyme-linked immune sorbent assay [ELISA]), and typical imaging findings (US, CT and MRI). Seven patients were evaluated for an initial diagnosis; one was diagnosed with HAE and had received oral drug therapy for three years. Eight patients had MRI and PET/CT examination within one week prior to each study.
For image acquisition, the same protocol was adopted for all examinations using a clinical 3T MR system (Signa Exite HD; GE Healthcare, Milwaukee, WI, USA) with a eight-channel phased-array torso surface coil. The conventional MRI protocol consisted of transverse unenhanced T1-weighted images (T1WI) and respiratory-triggered T2-weighted images (T2WI). A respiratory-triggered single shot fat suppressed echo planar DWI sequence was acquired with the gradient factors (b-values were 0 and 800 s/mm2). Consequently, the corresponding apparent diffusion coefficient (ADC) map was generated using ADW 4.2 scanner software (GE Healthcare).
All PET/CT examinations were performed on a PET/CT scanner (Discovery VCT; GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA). All patients fasted for at least eight hours before the administration of an injection containing FDG at 4.8 MBq/kg body weight. PET/CT scans were performed 60 minutes after the injection of the FDG. A whole-body emission PET scan with a 70-cm axial field of view, a 218 x 218 matrix, a slice thickness of 4.25 mm was performed with five bed positions within 20 minutes. The PET and CT fusion images were obtained by image reconstruction in cross, coronal, and sagittal sections.
Two different radiologists worked independently to determine the activity of HAE lesions. They used the following standard: (+) was used to mark focally or perilesionally increased FDG uptake/hyper-signal intensity. Conversely, (−) was used to mark a hepatic defect without FDG uptake/no hyper-signal intensity, on PET/CT and DWI respectively.
The region-of-interest (ROI) was placed on fused PET/CT, covering the metabolic activity area. Then, we performed a semi-quantitative analysis by extracting the maximum standardized uptake value (SUVmax) from each lesion's PET images, defined as maximum SUV value within the delineated viability area. Also, a polygonal ROI was placed manually on every ADC slice encompassing the entire viability area appearing as an area of low signal intensity. We calculated mean ADC value within all ADC slices displaying the metabolic activity area.
We performed our statistical analysis using the SPSS software package (version 18.0; SPSS Inc., Chicago, IL, USA). We used Pearson's correlation coefficient to determine the relationship of ADC and SUVmax data and p values < 0.01 were considered significant.
We detected fourteen HAE lesions in all eight patients. Three patients underwent liver transplantation and the associated treatment follow-up. Two patients underwent radical HAE lesions resection, while three others had non-radical hepatic resection. Liver transplantation or non-radical resection was performed, because the parasitic disease massively involved either both lobes of the liver (2 cases), the common portal vein (1 case), both the right and left bile ducts (1 case), retrohepatic segment of the vena cava (1 case), and the diaphragm (1 case). In all of these cases, radical resection would have been very risky. All of these patients received pharmacological treatment with benzimidazoles for at least two years (for those who underwent liver transplantation or radical lesions resection) or long-term (for those non-radical hepatic resection).
On the DWI (b = 800 s/mm2), nine large HAE lesions (ranging from 3–15 cm in diameter) presented as lesions with internal mixed signal intensity. The necrotic area showed a high-signal intensity, while the solid part showed varied appearances of low- or high-signal intensity. Eight of them could be detected with a perilesional high-signal intensity on DWI and with a low-signal intensity on an ADC map. It mainly existed in the lesion's border with normal liver parenchyma, but not in the liver capsule and diaphragm area. The conventional sequence, both T1WI and T2WI, failed to demonstrate the perilesional high-signal intensity in all 14 lesions (Fig. 1). Five small nodules (diameter < 2 cm) presented as nodular, with a high-signal intensity on DWI and slightly lower signal intensity on ADC map (Fig. 2). In a patient who had been receiving oral drug therapy for three years, the perilesional high-signal intensity on DWI persisted. However, it had significantly decreased and it was no longer consistent with the image taken at the initial diagnosis (Fig. 3).
Eight of 14 lesions could be detected as dotted or tiny, circled calcifications within the mass on CT images, which was a feature for HAE diagnosis. The treated HAE lesion presented as a hepatic defect without any FDG uptake on post-treatment PET/CT (Fig. 3). The other 13 initially-diagnosed lesions could be visualised as an internal filling defect with a peripheral increased FDG uptake, which mainly existed in the lesion's border with normal liver parenchyma (n = 8), or the whole nodular “hot spot” (n = 5) (Figs. 1, 2).
In this group, one patient suffered two cystic echinococcosis (CE) lesions and five HAE lesions. The CE lesion was seen as a cystic lesion without any viability on both DWI and PET/CT (Fig. 2).
The patients' characteristics, HAE distribution, and details of DWI and PET/CT findings in depicting the viability were shown in Table 1. The ADC and SUVmax were compared on a per-lesion basis. Pearson's correlation coefficient (r = −0.67; p < 0.001) indicated a significant inverse correlation of the ADC and the SUVmax, as displayed in the scatter plot (Fig. 4).
MRIs, with its conventional sequences, such as T1WI, T2WI and enhanced T1-weighted sequences, have been used for the diagnosis of HAE and the corresponding complications in previous studies (78). While DWI had only been utilized in one previous study, it had demonstrated its value. DWI was able to illuminate characteristics of HAE lesions according to Kodama's classification system; however, no mention was made on its role in viability in this research (9).
Diffusion-weighted imaging is based on the physical process of random Brownian motion of water molecules in the body. Diffusion of intracellular water molecules is restricted by the presence of cell and organelle membranes. In highly-cellular tissues, such as neoplasm, diffusion is restricted due to the smaller extra-cellular volume and higher density of hydrophobic cellular membranes. There is good evidence that DWI has the potential to improve lesion detection rates and contribute to the evaluation and characterization of hepatic lesions (1011).
In the current research, an association was demonstrated between DWI and PET/CT in depicting the metabolic activity of HAE, in terms of both their intensity and distribution. Previous oncologic studies would serve to confirm this phenomenon.
For example, DWI showed a close distribution with PET/CT for the evaluation of malignancy of lymph node metastasis in the head and neck, indicating the existence of a relationship between the density and metabolic activity of tumor cells (12).
Hepatic alveolar echinococcosis grows multifocally and invasively, with protrusions of its germinal layer into the host tissue causing an intense inflammatory reaction, granuloma formation, and increased radiotracer uptake on the FDG-PET-CT (1314). Restricted water diffusion caused by inflammatory cell infiltration can also be detected with DWI. Therefore, the same nature of HAE inflammatory granuloma was disclosed from different aspects via two technologies. In a comparative study of malignant tumors, a correlation analysis was conducted between the respective quantitative indicators, the ADC and the SUV of DWI and PET/CT (15).
In this study, we found a significant inverse correlation between the SUVmax and the ADC. This correlation, to a certain degree, supports the assumption that DWI might be of value in assessing the viability of HAE as PET/CT does.
As mentioned earlier, in one of our cases, a patient underwent oral drug therapy for three years. For this patient, the perilesional high-signal intensity in the DWI was still present but significantly decreased, while the PET/CT scans showed a hepatic defect without any FDG uptake. This was only the discrepancy between PET/CT and DWI in our study. We attribute the discrepancy as possibly being caused by a false-positive DWI, or false-negative PET/CT. Criteria of cure for a patient with an inoperable lesion (that is, criteria for non-viable lesion) are still unsettled, but should include a negative PET/CT scan, calcified component of the alveolar echinococcosis lesion of more than 50% as well as the disappearance of specific antibodies (1). If based on this criteria, this treated case should still have had a viable lesion (a negative PET/CT, while no obvious calcification, equivocal specific antibodies).
It was reported that PET negativity does not necessarily indicate non-activity of the parasite (13). After chemotherapy, the HAE metabolic activity can be too low for detection with PET, and/or positivity of very small peripheral foci may be missed due to the limited spatial resolution (5 mm) of the PET scanner. Due to our limited experience and without any other study references, we cannot conclude that DWI is more sensitive in detecting parasitic vitality after benzimidazole therapy than PET/CT does. However, whether DWI is more sensitive may be worth exploring in further studies.
In our study, five small lesions (< 2 cm in diameter) presented as increased nodular metabolic activity both on DWI and PET/CT due to multiple granulomas fused together. In the larger lesions, the central part without any viability consisted of fibrotic tissue, coagulation necrosis, liquefaction necrosis and/or calcifications. The activity was distributed in a pattern of central “filling defects” and lateral “hot spots,” which mainly existed in the lesion's border with normal liver parenchyma. While a lesion will show activity reduction or inactivity in the liver capsular and diaphragm area (341316), in most cases, E. multilocularis will develop parasitic activity characterized by unidirectional growth. Therefore, one extreme of a parasitic lesion may show metabolic activity while the polar opposite consists of necrotic tissue, which is why fine-needle biopsy is not recommended as a conventional viability assessing technique (4).
Even knowing this, it is still hard to explain the phenomenon that inactivity is always found near the liver capsular and diaphragm area. Could it be said that those fibrous membranes play some role in stopping the development, or even gradually causing partial death of the parasite? Whether this so-called “contact trigger death” exists or not requires further research.
Prior to making our conclusions, we note the limitations of this study. Particularly, we note that the overall number of included patients (eight) was small, and only one patient underwent follow-up repeated imaging. Therefore, we may only conclude that DWI and PET/CT may agree well in terms of characterizing initial active HAE, and their agreement on treated or inactive HAE needs further study.
In conclusion, DWI is comparable to PET/CT in visually detecting the viability of HAE lesion. Significant inverse correlations were found between ADC from DWI and SUVmax from PET/CT on data of HAE lesions. This finding indicates that DWI is potentially capable of offering similar information for evaluating metabolic activity in HAE patients as well as PET/CT does.
References
1. Brunetti E, Kern P, Vuitton DA. Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010; 114:1–16. PMID: 19931502.
2. Buttenschoen K, Carli Buttenschoen D, Gruener B, Kern P, Beger HG, Henne-Bruns D, et al. Long-term experience on surgical treatment of alveolar echinococcosis. Langenbecks Arch Surg. 2009; 394:689–698. PMID: 18651165.
3. Crouzet J, Grenouillet F, Delabrousse E, Blagosklonov O, Thevenot T, Di Martino V, et al. Personalized management of patients with inoperable alveolar echinococcosis undergoing treatment with albendazole: usefulness of positron-emission-tomography combined with serological and computed tomography follow-up. Clin Microbiol Infect. 2010; 16:788–791. PMID: 19912267.
4. Reuter S, Schirrmeister H, Kratzer W, Dreweck C, Reske SN, Kern P. Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography. Clin Infect Dis. 1999; 29:1157–1163. PMID: 10524957.
5. Kim H, Lee JM, Yoon JH, Jang JY, Kim SW, Ryu JK, et al. Reduced field-of-view diffusion-weighted magnetic resonance imaging of the pancreas: comparison with conventional single-shot echo-planar imaging. Korean J Radiol. 2015; 16:1216–1225. PMID: 26576110.
6. Pauls S, Schmidt SA, Juchems MS, Klass O, Luster M, Reske SN, et al. Diffusion-weighted MR imaging in comparison to integrated [18F]-FDG PET/CT for N-staging in patients with lung cancer. Eur J Radiol. 2012; 81:178–182. PMID: 20932700.
7. Kantarci M, Bayraktutan U, Karabulut N, Aydinli B, Ogul H, Yuce I, et al. Alveolar echinococcosis: spectrum of findings at cross-sectional imaging. Radiographics. 2012; 32:2053–2070. PMID: 23150858.
8. Kodama Y, Fujita N, Shimizu T, Endo H, Nambu T, Sato N, et al. Alveolar echinococcosis: MR findings in the liver. Radiology. 2003; 228:172–177. PMID: 12750459.
9. Becce F, Pomoni A, Uldry E, Halkic N, Yan P, Meuli R, et al. Alveolar echinococcosis of the liver: diffusion-weighted MRI findings and potential role in lesion characterisation. Eur J Radiol. 2014; 83:625–631. PMID: 24457140.
10. Ahn JH, Yu JS, Cho ES, Chung JJ, Kim JH, Kim KW. Diffusion-weighted MRI of malignant versus benign portal vein thrombosis. Korean J Radiol. 2016; 17:533–540. PMID: 27390544.
11. Culverwell AD, Sheridan MB, Guthrie JA, Scarsbrook AF. Diffusion-weighted MRI of the liver-Interpretative pearls and pitfalls. Clin Radiol. 2013; 68:406–414. PMID: 22981728.
12. Lin C, Itti E, Luciani A, Zegai B, Lin SJ, Kuhnowski F, et al. Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study. Invest Radiol. 2011; 46:341–349. PMID: 21263330.
13. Stumpe KD, Renner-Schneiter EC, Kuenzle AK, Grimm F, Kadry Z, Clavien PA, et al. F-18-fluorodeoxyglucose (FDG) positron-emission tomography of Echinococcus multilocularis liver lesions: prospective evaluation of its value for diagnosis and follow-up during benzimidazole therapy. Infection. 2007; 35:11–18. PMID: 17297583.
14. Vuitton DA, Gottstein B. Echinococcus multilocularis and its intermediate host: a model of parasite-host interplay. J Biomed Biotechnol. 2010; 2010:923193. PMID: 20339517.
15. Regier M, Derlin T, Schwarz D, Laqmani A, Henes FO, Groth M, et al. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)? Eur J Radiol. 2012; 81:2913–2918. PMID: 22197090.
16. Caoduro C, Porot C, Vuitton DA, Bresson-Hadni S, Grenouillet F, Richou C, et al. The role of delayed 18F-FDG PET imaging in the follow-up of patients with alveolar echinococcosis. J Nucl Med. 2013; 54:358–363. PMID: 23303963.
Table 1
In patients 4, 5, and 8, ADC and SUVmax were measured in two or more lesions. *Patient with initial diagnosis and follow-up. AbEm2+ = specific antibody to HAE, ADC = apparent diffusion coefficient, BMZ = benzimidazole therapy, HAE = hepatic alveolar echinococcosis, N = number of lesions, SUVmax = maximum standardized uptake value